Ｚｏｍｅｐｉｒａｃ ＳｏｄｉｕｍとＡｓｐｉｒｉｎのＰａｉｎ Ｍｅｔｅｒによる鎮痛効果の検討 [in Japanese] A Study of the Analgesic Effect of Zomepirac Sodium Based on Pain Meter Measurements [in Japanese]
Access this Article
Search this Article
Zomepirac sodium is a new non-narcotic analgesic antiphlogistic developed by McNeil Laboratories, U. S. A., particularly noted for its strong analgesic effect upon oral administration.<BR>As reported in this paper, a comparative study of the analgesic effect of zomepirac sodium was conducted in comparison with aspirin and a placebo based on pain meter measurements.<BR>The pain meter used was the Nakahama-type NYT-model 5 which is an improved version of the original pain meter developed by Hardy et al.<BR>Two methods were used in recording pain: The intensity method in which the duration of the stimulus was set at a fixed standard and the amount of radiant energy was measured and the time method in which the amount of radiant energy was set at a fixed standard and the duration of the pain was measured.<BR>The subjects were 9 healthy male volunteers who were divided into three groups, namely the 200 mg zomepirac group, the 500 mg aspirin group and the placebo group.Measurements were taken on the hand, leg, and breast.<BR>The results obtained indicate that it is impossible to detect any significant difference between zomepirac sodium, aspirin and the placebo in either the time or intensity methods.<BR>It is said that in general such non-narcotic analgesics as zomepirac sodium do not respond well to mechanical stimuli such as used during this experiment and our results support this conclusion. This analgesic exhibits quite different characteristics in comparison with CNS analgesics such as pentazocine.
- Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 13(2), 221-227, 1982
The Japanese Society of Clinical Pharmacology and Therapeutics